Jasper Therapeutics faces financial challenges but strong buy ratings. Read why JSPR stock is poised for growth amid risks ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Analyst Ami Fadia of Needham maintained a Buy rating on Blueprint Medicines (BPMC – Research Report), retaining the price target of ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...

ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, <a target= ...

Antihistamines for systemic use constituted the majority of additional medications for urticaria used in all treatment groups (100% in the levocetirizine and 78.8% in the placebo group).

In November 2021, however, she came up against a case nearly impossible to solve. It all started when Elisha woke up with an ...

Frieden was director of the Centers for Disease Control and Prevention from 2009-2017. Donald Trump and Robert F. Kennedy Jr.’s campaign to “Make America Healthy Again” gets some things ...

Medically reviewed by Jurairat J. Molina, MD Acute urticaria (hives) is a common skin condition that affects up to 20% of people at some point in their lives. It can transition into chronic urticaria ...